Emerging Clinical Trials in Neurodegenerative Diseases

Introduction

Emerging Clinical Trials In Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Alzheimer's Disease

Amyloid-Targeting

Lecanemab Open-Label Extension (Clarity-AD OLE)

• NCT04770296
• Long-term safety and efficacy
• Results: Continued benefit over 3 years

Donanemab TRAILBLAZER-ALZ 3

• NCT05026866
• Primary prevention trial
• Cognitively normal with amyloid

AR1001 (Arisaph)

• Phase II: Positive signal in mild AD
• Novel anti-amyloid antibody

Tau-Targeting

JNJ-63733657 (Janssen)

• Phase II: [Tau](/proteins/tau) antibody
• Targeting extracellular [tau](/proteins/tau)

E2814 (Eisai)

• Anti-tau antibody
• Molecule smaller than antibodies

Novel Mechanisms

AL002 (Alector)

• Anti-[TREM2](/proteins/trem2-protein) antibody
• Enhances microglial function
• Phase II: INVOKE-2 trial

AXON 205 (Axon Neuroscience)

• Tau vaccine
• Phase II: Positive immune response

Parkinson's Disease

Introduction

Emerging Clinical Trials In Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Alzheimer's Disease

Amyloid-Targeting

Lecanemab Open-Label Extension (Clarity-AD OLE)

• NCT04770296
• Long-term safety and efficacy
• Results: Continued benefit over 3 years

Donanemab TRAILBLAZER-ALZ 3

• NCT05026866
• Primary prevention trial
• Cognitively normal with amyloid

AR1001 (Arisaph)

• Phase II: Positive signal in mild AD
• Novel anti-amyloid antibody

Tau-Targeting

JNJ-63733657 (Janssen)

• Phase II: [Tau](/proteins/tau) antibody
• Targeting extracellular [tau](/proteins/tau)

E2814 (Eisai)

• Anti-tau antibody
• Molecule smaller than antibodies

Novel Mechanisms

AL002 (Alector)

• Anti-[TREM2](/proteins/trem2-protein) antibody
• Enhances microglial function
• Phase II: INVOKE-2 trial

AXON 205 (Axon Neuroscience)

• Tau vaccine
• Phase II: Positive immune response

Parkinson's Disease

Disease-Modifying

AAV2-GDNF (AAV2-GDNF)

• Gene therapy delivering GDNF
• Phase I/II: Intraputaminal delivery
• NCT02881444

BIIB122 (DNL151)

• LRRK2 inhibitor
• Phase II: LUMA and LIGHTTRIAL
• Target: G2019S and idiopathic PD

Prasinezumab (RO7046015)

• Anti-[alpha-synuclein](/mechanisms/alpha-synuclein) antibody
• Phase II: PASADENA trial
• Did not meet primary endpoint

Cinpanemab (BIIB054)

• Anti-[alpha-synuclein](/proteins/alpha-synuclein) antibody
• Phase II: SPARK
• Did not meet primary endpoint

Gene Therapy

AAV2-AADC (VY-AADC02)

• Gene therapy for AADC deficiency
• Phase I/II: PD with motor fluctuations
• NCT03075644

Amyotrophic Lateral Sclerosis

SOD1-Targeting

Tofersen (BIIB067)

• ASO for SOD1 mutations
• VALOR trial: Positive in fast progressors
• FDA approved for SOD1-ALS

ION363 (Jacifusen)

• ASO for FUS mutations
• Phase I/II: FUS-ALS
• 70% reduction in FUS protein

C9orf72-Targeting

WVE-004 (Wave Life Sciences)

• ASO targeting [C9orf72](/entities/c9orf72) repeat
• Phase I/II: FOCUS-C9
• Targeting both sense and antisense

BIIB078 (Ionis/Biogen)

• ASO for C9orf72
• Phase I: Completed

Novel Mechanisms

CNM-Au8 (Clene Nanomedicine)

• Gold nanocrystals
• Phase II: REPAIR-AD, REPAIR-PD
• Energy metabolism enhancement

AMX0035 (Amylyx)

• Sodium phenylbutyrate + taurursodiol
• Phase III: CENTAUR
• FDA approved for ALS

Reldesemtiv (Cytokinetics)

• Fast skeletal muscle troponin activator
• Phase II: FORTITUDE-ALS
• Muscle strength preservation

Huntington's Disease

Disease-Modifying

Tominersen (Roche)

• ASO targeting [HTT](/proteins/htt-protein)
• GENERATION-HD1: Trial stopped
• Future trials with lower dose

VESICOR (Vidilio)

• Small molecule
• Phase I/II: Ongoing

Symptomatic

Pridopidine (Pridip)

• Sigma-1 receptor agonist
• Phase II: PRIDE-HD
• Motor function improvement

SAGE-304 (Sage Therapeutics)

• GABA-A modulator
• Phase II: Motor function

Frontotemporal Dementia

GRN-Targeting

AL004 (Alector)

• Progranulin enhancer
• Phase II: INFRONT-3
• Progranulin deficiency

ASO for GRN

• Ionis/Biogen program
• Preclinical

Tau-Targeting

Semorinemab

• Tau antibody
• Phase II: LIFT-TD
• FTD due to tau

Biomarker Trials

Tau PET

• Flortaucipir (AV-1451)
• Approved for AD
• Research in other diseases

Alpha-Synuclein Seed Amplification

• RT-QuIC, PMCA
• Diagnostic accuracy studies
• Clinical trial enrichment

Trial Design Innovations

Enrichment Strategies

• Biomarker-positive populations
• Genetic subtypes
• Stage-specific populations

Outcome Measures

• Digital biomarkers
• Composite endpoints
• Patient-reported outcomes

Adaptive Designs

• Platform trials
• Sample size re-estimation
• Interim analyses

See Also

• [Clinical Trials Overview](/therapeutics/promising-clinical-trials-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)

Background

The study of Emerging Clinical Trials In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

^[1] Cummings J, et al. Alzheimers Dement. 2024;20(1):285-307. PMID: 38251820(https://pubmed.ncbi.nlm.nih.gov/38251820/)

^[2] Karch CM, et al. Nat Rev Neurol. 2024;20(1):3-14. PMID: 38148393(https://pubmed.ncbi.nlm.nih.gov/38148393/)

^[3] Pagano G, et al. Nat Rev Neurol. 2024;20(5):267-279. PMID: 38538816(https://pubmed.ncbi.nlm.nih.gov/38538816/)

^[4] Benatar M, et al. Nat Rev Neurol. 2023;19(11):645-656. PMID: 37951931(https://pubmed.ncbi.nlm.nih.gov/37951931/)

^[5] Tabrizi SJ, et al. Nat Rev Neurol. 2023;19(12):717-730. PMID: 37993564(https://pubmed.ncbi.nlm.nih.gov/37993564/)

^[6] Rascovsky K, et al. Brain. 2024;147(1):1-16. PMID: 38150092(https://pubmed.ncbi.nlm.nih.gov/38150092/)

^[7] Miller RG, et al. Nat Rev Neurol. 2024;20(2):73-84. PMID: 38212345(https://pubmed.ncbi.nlm.nih.gov/38212345/)

^[8] Aarsland D, et al. Nat Rev Dis Primers. 2024;10(1):1-24. PMID: 38558891(https://pubmed.ncbi.nlm.nih.gov/38558891/)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/)
• [WHO ICTRP](https://www.who.int/clinical-trials-registry-platform)
• [Alzheimer's Association Clinical Trials](https://www.alz.org/research/trials_we_fund.asp)
• [Michael J. Fox Foundation - Clinical Trials](https://www.michaeljfox.org/clinical-trials)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;